Valuation: Annexon, Inc.

Market Cap 682M 607M 562M 512M 965M 64.77B 981M 6.76B 2.65B 33.8B 2.56B 2.51B 108B P/E 2026 *
-3.47x
P/E 2027 * -3.67x
Enterprise Value 604M 537M 498M 453M 854M 57.32B 868M 5.98B 2.35B 29.91B 2.27B 2.22B 95.36B EV / Sales 2026 *
-
EV / Sales 2027 * 15.9x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day-5.42%
1 week-15.67%
Current month-19.86%
1 month-13.74%
3 months-42.44%
6 months-46.45%
Current year-32.47%
1 week 3.39
Extreme 3.39
4.06
1 month 3.39
Extreme 3.39
4.38
Current year 3.39
Extreme 3.39
7.18
1 year 2.54
Extreme 2.54
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
21.87
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 30/11/2014
Director of Finance/CFO 53 31/05/2019
Chief Tech/Sci/R&D Officer 68 26/07/2023
Director TitleAgeSince
Director/Board Member 58 30/11/2014
Director/Board Member 67 04/02/2021
Director/Board Member 56 31/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/26 Buy

Chief Executive Officer

26,065 0.0137%
10/08/26 Free

Director

175,000 0.0923%
28/05/26
Alerce Investment Management LP
BuyCompany 613,497 0.3775%
Change 5-day change 1-year change 3-year change Capi.($)
-5.42%-15.67%+6.94%+84.24% 682M
-6.60%-10.93%+45.08%+60.01% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-0.98%+3.25%+30.42%+34.86% 44.61B
-5.66%-6.16%+258.45%+421.92% 40.57B
-1.56%+4.08%+16.01%+112.11% 42.53B
+6.53%+8.02%+18.98%+54.58% 30.95B
-0.90%-10.91%+34.11%-1.83% 25.44B
-2.48%-9.04%-16.07%-9.05% 22.66B
Average -2.16%+0.37%+40.64%+85.34% 38.04B
Weighted average by Cap. -2.40%+1.63%+45.66%+89.67%

Financials

2026 *2027 *
Net sales - 38.92M 34.59M 32.06M 29.17M 55.05M 3.69B 55.93M 385M 151M 1.93B 146M 143M 6.14B
Net income -212M -188M -174M -159M -299M -20.09B -304M -2.1B -822M -10.48B -794M -777M -33.41B -209M -186M -172M -157M -296M -19.87B -301M -2.07B -813M -10.37B -786M -769M -33.05B
Net Debt -78.52M -69.8M -64.69M -58.86M -111M -7.45B -113M -778M -305M -3.89B -295M -288M -12.4B -63.35M -56.31M -52.19M -47.48M -89.61M -6.01B -91.04M -627M -246M -3.14B -238M -233M -10B
Projected Income Statement - Annual - Annexon, Inc.
Logo Annexon, Inc.
Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis.
Employees
92
Date Price Change Volume
16/10/26 US$3.395 -5.69% 1,639,227
15/10/26 US$3.600 -1.91% 2,653,845
14/10/26 US$3.670 -4.18% 4,042,922
13/10/26 US$3.830 -3.28% 3,421,698
12/10/26 US$3.960 -1.49% 1,927,485
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Annexon, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.600USD
Average target price
15.43USD
Spread / Average Target
+328.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Annexon, Inc.
  1. Stock Market
  2. Stocks
  3. ANNX Stock